Sommario

Bibliografia
1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837- 2. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997 3. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553, 1998 4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837- 5. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 6. Smelo LS: University group diabetes program. JAMA 215:2115, 1971 7. Coutinho, M., Gerstein, H. C., Wang, Y., and Yusuf, S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 8. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354:617-621, 1999 9. Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21:360-367, 1998 10. Malmberg K, Norhammar A, Wedel H, Ryden L: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 11. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. 12. Van de Berghe G, Wouters P, Weekers F, Verwaest F, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive Insulin therapy in critically ill patients. N Engl J Med 345:1359-1367, 2001 13. Rotella CM, Mannucci E, Cresci B, Giannini S, Tesi F: IL DIABETE MELLITO - Criteri Diagnostici e Terapeutici: un aggiornamento. Florence, 2003 14. Renstrom E, Barg S, Thevenod F, Rorsman P: Sulfonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K+ channel-independent action. Diabetes 51 15. Leahy, J. L., Cooper, H. E., Deal, D. A., and Weir, G. C. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. J Clin Invest 77, 16. Asmal AC, Marble A: Oral hypoglycaemic agents. An update. Drugs 28:62-78, 1984 17. Rosskamp R, Wernicke P, Draeger E: Clinical profile of the novel sulphonylurea glimepiride. Diabetes Res Clin Pract 31 Suppl:S33-S42, 1996 18. Keller U, Muller R, Berger W: Sulfonylurea therapy fails to diminish insulin resistance in type I-diabetic subjects. Horm Metab Res 18:599-603, 1986 19. Rosenstock, J., Samols, E., Muchmore, D. B., and Schneider, J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Ggroup. Diabetes Care 19, 1194-1199. 1996. 20. Gribble FM, Ashcroft FM: Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Diabetologia 42:845-848, 1999 21. Landstedt H, Englund A, Adamson U, Lins PE: Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med 246:299-307, 22. Najeed SA, Khan IA, Molnar J, Somberg JC: Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K+ channel effect. Am J Cardiol 90:1103-1106, 2002 23. Asplund K, Wiholm BE, Lithner F: Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 24:412-417, 1983 24. Holstein A, Plaschke A, Egberts EH: Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17:467-473, 25. Melander A, Bitzen PO, Faber O, Groop L: Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use. Drugs 37:58-72, 26. Ovunc K: Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris. Clin 27. Murry, C. E., Jennings, R. B., and Reimer, K. A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74, 1124-1136. 1986. 28. Reimer KA, Murry CE, Jennings RB: Cardiac adaptation to ischemia. Ischemic preconditioning increases myocardial tolerance to subsequent ischemic episodes. 29. Engler RL, Yellon DM: Sulfonylurea KATP blockade in type 2 diabetes and preconditioning in cardiovascular disease: time for reconsideration. Circulation 30. Heusch G: Nitroglycerin and delayed preconditioning in humans: yet another new mechanism for an old drug? Circulation 103:2876-2878, 1901 31. Scognamiglio R, Avogaro A, Vigili d, Negut C, Palisi M, Bagolin E, Tiengo A: Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 51:808-812, 2002 32. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854-865, 1998 33. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. 34. Brady PA, Terzic A: The sulfonylurea controversy: more questions from the heart. J 35. Fasching P: Possible risk of sulphonylureas in the treatment of non-insulin- dependent diabetes mellitus and coronary artery disease. Diabetologia 41:743-744, 36. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR, Jr.: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 33:119-124, 37. Meier JJ, Deifuss S, Klamann A, Schmiegel W, Nauck MA: Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp Clin Endocrinol Diabetes 111:344-350, 2003 38. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R: Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 25:472-484, 2003 39. Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A: Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. 40. Rizzo MR, Barbieri M, Grella R, Passariello N, Barone M, Paolisso G: Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study. Diabetes Metab 41. Hirshberg B, Skarulis MC, Pucino F, Csako G, Brennan R, Gorden P: Repaglinide- induced factitious hypoglycemia. J Clin Endocrinol Metab 86:475-477, 2001 42. Wolffenbuttel BH: Repaglinide--a new compound for the treatment of patients with type 2 diabetes. Neth J Med 55:229-234, 1999 43. Hu, S., Wang, S., and Dunning, B. E. Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell K(ATP) channel. J Pharmacol 44. Krogsgaard TM, Bokvist K, Hoy M, Buschard K, Holst JJ, Lindstrom P, Gromada J: Repaglinide at a cellular level. Diabetes Nutr Metab 15:15-18, 2002 45. Malaisse WJ: Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. Eur J Clin Invest 29 Suppl 2:21-29, 1999 46. Fulhendorf, J., Rorsman, P., Kofold, H., Brand, C. L., Rolin, B., MacKay, P., Shymko, R., and Carr, R. D. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct process. Diabetes 47, 345-351. 47. Landgraf R, Bilo HJ, Muller PG: A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 55:165-171, 1999 48. Wolffenbuttel BH, Landgraf R: A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 22:463-467, 1999 49. Culy CR, Jarvis B: Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 61:1625-1660, 2001 50. Tessier D, Dawson K, Tetrault JP, Bravo G, Meneilly GS: Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 11:974-980, 1994 51. Malaisse WJ: Repaglinide, a new oral antidiabetic agent: a review of recent preclinical studies. Eur J Clin Invest 29 Suppl 2:21-29, 1999 52. Marbury T, Huang WC, Strange P, Lebovitz H: Repaglinide versus glyburide: a one- year comparison trial. Diabetes Res Clin Pract 43:155-166, 1999 53. Hu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R., and Boetcherr, B. R. Pancreatic beta-cell K(ATP) channel activity and membrane- binding studies with nateglinide: A comperison with sulfonylureas and repaglinide. J 54. Del Prato M, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP: Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care 26:2075-2080, 2003 55. Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C: Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 4:177-186, 56. Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, Schwanebeck U, Julius U: Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 14:308-317, 1991 57. Kalbag JB, Walter YH, Nedelman JR, McLeod JF: Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. 58. Chiasson JL, Rabasa-Lhoret R: Prevention of type 2 diabetes: insulin resistance and beta-cell function. Diabetes 53 Suppl 3:S34-S38, 2004 59. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 60. Boden, G., Chen, X., Capulong, E., and Mozzoli, M. Effect of free fat acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. 61. Gomez P, Fanghanel S, Antonio B, Montes V, Berry RA, Warsi G, Gould EM: Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 18:127-134, 2001 62. Forsen L, Meyer HE, Midthjell K, Edna TH: Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 42:920- 63. Nicodemus KK, Folsom AR: Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-1197, 2001 64. Vogt MT, Rubin D, Valentin RS, Palermo L, Donaldson WF, III, Nevitt M, Cauley JA: Lumbar olisthesis and lower back symptoms in elderly white women. The Study of Osteoporotic Fractures. Spine 23:2640-2647, 1998 65. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR: Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32-38, 66. Carnevale V, Romagnoli E, D'Erasmo E: Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 20:196-204, 2004 67. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404- 68. de L, II, van der KM, de Laet CE, van Daele PL, Hofman A, Pols HA: Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713-1720, 2005 69. Lipscombe LL, Jamal SA, Booth GL, Hawker GA: The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 30:835-841, 70. Janghorbani M, Feskanich D, Willett WC, Hu F: Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care 29:1573-1578, 2006 71. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de RN, Harris TB, Newman AB: Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165:1612-1617, 2005 72. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR: Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32-38, 73. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404- 74. de L, II, van der KM, de Laet CE, van Daele PL, Hofman A, Pols HA: Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713-1720, 2005 75. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de RN, Harris TB, Newman AB: Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165:1612-1617, 2005 76. van Daele PL, Stolk RP, Burger H, Algra D, Grobbee DE, Hofman A, Birkenhager JC, Pols HA: Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med 122:409-414, 1995 77. Tuominen JT, Impivaara O, Puukka P, Ronnemaa T: Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 22:1196-1200, 1999 78. Lunt M, Masaryk P, Scheidt-Nave C, Nijs J, Poor G, Pols H, Falch JA, Hammermeister G, Reid DM, Benevolenskaya L, Weber K, Cannata J, O'Neill TW, Felsenberg D, Silman AJ, Reeve J: The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: the EVOS study. 79. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404- 80. Carnevale V, Romagnoli E, D'Erasmo E: Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 20:196-204, 2004 81. de L, II, van der KM, de Laet CE, van Daele PL, Hofman A, Pols HA: Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713-1720, 2005 82. Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O'Neil J: Biphasic fracture risk in diabetes: a population-based study. Bone 40:1595-1601, 2007 83. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Zmuda JM, Bauer DC, Tylavsky FA, de RN, Harris TB, Newman AB: Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone 84. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de RN, Harris TB, Newman AB: Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165:1612-1617, 2005 85. Vestergaard P, Rejnmark L, Mosekilde L: Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292-1299, 2005 86. Vestergaard P, Rejnmark L, Mosekilde L: Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292-1299, 2005 87. Carnevale V, Romagnoli E, D'Erasmo E: Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 20:196-204, 2004 88. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404- 89. Forsen L, Meyer HE, Midthjell K, Edna TH: Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 42:920- 90. Nicodemus KK, Folsom AR: Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-1197, 2001 91. Vogt MT, Rubin D, Valentin RS, Palermo L, Donaldson WF, III, Nevitt M, Cauley JA: Lumbar olisthesis and lower back symptoms in elderly white women. The Study of Osteoporotic Fractures. Spine 23:2640-2647, 1998 92. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR: Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32-38, 93. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404- 94. Vestergaard P, Rejnmark L, Mosekilde L: Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292-1299, 2005 95. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR: Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354, 2006 96. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR: The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305-1310, 2007 97. Yaturu S, Bryant B, Jain SK: Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30:1574-1576, 2007 98. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006 99. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406, 2004 100. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC: Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J 101. Thrailkill KM, Lumpkin CK, Jr., Bunn RC, Kemp SF, Fowlkes JL: Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 289:E735-E745, 2005 102. Nicodemus KK, Folsom AR: Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-1197, 2001 103. Vogt MT, Rubin D, Valentin RS, Palermo L, Donaldson WF, III, Nevitt M, Cauley JA: Lumbar olisthesis and lower back symptoms in elderly white women. The Study of Osteoporotic Fractures. Spine 23:2640-2647, 1998 104. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR: Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32-38, 105. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404- 106. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894:i-253, 2000 107. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, Neal B, Rodgers A, Ni MC, Clark T: 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub- committee of the World Health Organization. Clin Exp Hypertens 21:1009-1060, 108. Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 47:1245-1251, 1994 109. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR: Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354, 2006 110. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR: The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305-1310, 2007 111. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006 112. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406, 2004 113. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC: Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J 114. Thrailkill KM, Lumpkin CK, Jr., Bunn RC, Kemp SF, Fowlkes JL: Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 289:E735-E745, 2005 115. Carnevale V, Romagnoli E, D'Erasmo E: Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 20:196-204, 2004 116. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404- 117. de L, II, van der KM, de Laet CE, van Daele PL, Hofman A, Pols HA: Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713-1720, 2005 118. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de RN, Harris TB, Newman AB: Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165:1612-1617, 2005 119. Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O'Neil J: Biphasic fracture risk in diabetes: a population-based study. Bone 40:1595-1601, 2007 120. Forsen L, Meyer HE, Midthjell K, Edna TH: Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 42:920- 121. Nicodemus KK, Folsom AR: Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-1197, 2001 122. Vogt MT, Rubin D, Valentin RS, Palermo L, Donaldson WF, III, Nevitt M, Cauley JA: Lumbar olisthesis and lower back symptoms in elderly white women. The Study of Osteoporotic Fractures. Spine 23:2640-2647, 1998 123. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR: Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32-38, 124. Carnevale V, Romagnoli E, D'Erasmo E: Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 20:196-204, 2004 125. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404- 126. de L, II, van der KM, de Laet CE, van Daele PL, Hofman A, Pols HA: Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713-1720, 2005 127. Lipscombe LL, Jamal SA, Booth GL, Hawker GA: The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 30:835-841, 128. Janghorbani M, Feskanich D, Willett WC, Hu F: Prospective study of diabetes and risk of hip fracture: the Nurses' Health Study. Diabetes Care 29:1573-1578, 2006 129. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de RN, Harris TB, Newman AB: Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165:1612-1617, 2005 130. Forsen L, Meyer HE, Midthjell K, Edna TH: Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 42:920- 131. Nicodemus KK, Folsom AR: Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192-1197, 2001 132. Carnevale V, Romagnoli E, D'Erasmo E: Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 20:196-204, 2004 133. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404- 134. de L, II, van der KM, de Laet CE, van Daele PL, Hofman A, Pols HA: Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16:1713-1720, 2005 135. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de RN, Harris TB, Newman AB: Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165:1612-1617, 2005 136. Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O'Neil J: Biphasic fracture risk in diabetes: a population-based study. Bone 40:1595-1601, 2007 137. Carnevale V, Romagnoli E, D'Erasmo E: Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 20:196-204, 2004 138. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL: Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 91:3404-

Source: http://www.tesionline.com/__PDF/29086/29086b.pdf